The EFHD1 Knockout SK-HEP-1 Polyclonal Cells product provides a rigorously validated CRISPR/Cas9-edited polyclonal knockout cell population targeting the EFHD1 gene in the SK-HEP-1 human liver adenocarcinoma cell line. This loss-of-function model is generated by CRISPR/Cas9-mediated gene disruption within a polyclonal pool of SK-HEP-1 cells, offering a robust and versatile tool for studying EFHD1-dependent biological processes without the clonal selection biases inherent in single-cell-derived knockouts. The polyclonal format maintains genetic heterogeneity while ensuring functional ablation of EFHD1 across the population, making it suitable for both transient and stable knockout applications in cancer-related signaling and mitochondrial biology research.
SK-HEP-1 is an established human liver adenocarcinoma epithelial cell line originally isolated from the ascitic fluid of a patient with liver adenocarcinoma. This cell line is widely employed as a model system for hepatic cancer research due to its retention of key liver tumor characteristics, including dysregulated proliferation, altered metabolic activity, and metastatic potential. SK-HEP-1 cells have been extensively characterized in studies of hepatocellular carcinoma biology, drug resistance mechanisms, and tumor microenvironment interactions, making them a clinically relevant host for investigating the functional role of EFHD1 in liver cancer pathogenesis.
EFHD1 (Swiprosin-2) is a mitochondrial calcium-binding protein that plays a critical role in maintaining mitochondrial calcium homeostasis and regulating apoptosis. Mechanistically, EFHD1 interacts directly with mitofusin-2 (MFN2) to modulate mitochondrial calcium uptake through the mitochondrial calcium uniporter (MCU) complex, thereby influencing mitochondrial membrane potential and cytochrome c release. EFHD1 activity is regulated by upstream calcium signaling and epigenetic mechanisms such as DNA methylation, and it functions downstream of key calcium-dependent transcription factors. Its downstream signaling network includes modulation of the Bcl-2 family proteins, activation of caspase-3, and organization of the actin cytoskeleton through interactions with actin and MFN2, positioning EFHD1 as a node linking mitochondrial dynamics to cell fate decisions and cytoskeletal remodeling.
In the context of SK-HEP-1 liver adenocarcinoma cells, EFHD1 disruption holds significant relevance for understanding mitochondrial dysfunction in cancer. Aberrant mitochondrial calcium handling and apoptosis evasion are hallmarks of liver cancer, and EFHD1’s dual role in these pathways suggests it may contribute to tumor cell survival, metabolic adaptation, and resistance to chemotherapeutic agents. The EFHD1 knockout polyclonal cell population allows researchers to dissect the precise contributions of EFHD1 to mitochondrial homeostasis and apoptosis independently of other calcium-binding proteins, enabling the identification of EFHD1-specific vulnerabilities in liver adenocarcinoma cells.
This polyclonal knockout model is ideally suited for a wide range of experimental applications, including mitochondrial calcium imaging to assess real-time homeostasis, Annexin V/PI flow cytometry for quantitative apoptosis analysis, and western blotting to evaluate changes in downstream targets such as MFN2, Bcl-2, and caspase-3. Additional applications include cell viability and drug sensitivity profiling to uncover chemoresistance mechanisms, migration and invasion assays to study actin-dependent motility, RNA-seq for transcriptomic profiling of EFHD1-dependent gene networks, co-immunoprecipitation to map the EFHD1 interactome, and immunofluorescence microscopy to visualize mitochondrial morphology and actin cytoskeleton organization. For further technical details or to discuss how this model can accelerate your liver cancer research, please contact Ascent Research.
